FDA Advisory Opinion In BD Case Upholds 1996 Medtronic v. Lohr Ruling
This article was originally published in The Gray Sheet
Executive Summary
FDA consideration of preemption of requirements preventing BD's Easy A1C glycated hemoglobin home testing service kit from being marketed in certain states must be preceded by the firm's receipt of premarket approval application go-ahead, FDA maintains.